USNAMarch 5, 2026 at 6:03 AM UTCHealth Care Equipment & Services

USANA Turnaround Hype Clashes with DeepValue's Cautious Reality Check

Read source article

What happened

A Seeking Alpha article on March 5, 2026, portrays USANA as an undervalued turnaround stock, citing its pivot from MLM to high-growth brands Hiya and Rise Wellness with projected 23% revenue growth. However, the DeepValue master report reveals severe operational strains, including a 14% year-over-year decline in direct-selling active customers and a collapsed adjusted EBITDA margin of 6.4% in Q3 2025. The report notes that Hiya, despite contributing sales, remains loss-making with high SG&A costs, and FY25 guidance was cut to embed only modest improvement. Although the article highlights collaborations like Disney, it overlooks fundamental issues like customer attrition and margin compression that are not yet resolved. Thus, while the stock trades at a low EV/EBITDA of 2.54, the turnaround narrative lacks the evidence needed for confidence.

Implication

The Seeking Alpha article's optimism ignores critical weaknesses documented in the DeepValue report, such as persistent declines in active customers and EBITDA margins that have plummeted to 6.4%. USANA's low valuation multiples reflect market skepticism about its ability to execute the pivot, with the bear case scenario implying a $15 share price if trends worsen. Key catalysts like Q4 2025 results and the FY26 outlook must demonstrate progress in cost realignment and customer stabilization to shift the investment case. Without evidence of EBITDA margins recovering above 10% and active customer declines halting, the downside risk remains significant, and goodwill impairments could pressure the balance sheet. Therefore, maintaining the DeepValue 'WAIT' rating is prudent until concrete operational improvements emerge.

Thesis delta

The Seeking Alpha article promotes a bullish turnaround thesis, but it does not provide new data to shift the cautious stance from the DeepValue report. The report's thesis—that investors should wait for evidence of EBITDA margin recovery above 10% and stabilization in direct-selling active customers—remains unchanged. Optimistic commentary alone is insufficient to alter this view until quarterly results show tangible progress.

Confidence

high